Lundbeck announced that Vyepti™ (eptinezumab-jjmr) was approved by the FDA in February 2020 for the preventive treatment of migraine in adults and became available in April 2020.
Lundbeck began a phased launch of Vyepti in April. The first patients received infusions of Vyepti the day after the product was made available in the supply chain.
Lundbeck has an aggressive plan for maximizing the value of Vyepti. The first new indication the company plans to pursue is episodic cluster headache.
Lundbeck is working with payers to increase access to Vyepti with successful results with many, most notably Anthem, the second largest payer in the U.S. Lundbeck’s reimbursement support program, Vyepti Connect, and patient support program called Vyepti Go are helping increase access.
Vyepti is mainly focused on customers in clinics that have the capability to administer infusions and have experience doing in office procedures. These customers are most used to either buying and billing the product or working with a specialty pharmacy.
Orsini is a leading independent national specialty pharmacy focused on patients with rare and complicated diseases. Servicing patients in all 50 states, Orsini is a national specialty pharmacy that is a limited distribution partner for over 30 biotech manufacturers spanning a wide range of therapeutic specialties.
AllianceRx is a specialty and home delivery pharmacy that was formed in 2017 through a collaboration between Walgreens, one of the nation’s largest chain drug stores, and Prime Therapeutics, a leading pharmacy benefit manager.
Takeaway: Lundbeck selected two specialty pharmacies that are experienced dispensing limited distribution drugs and focus on complex conditions and treatment regimens that require a comprehensive patient and provider service model